Fremanezumab is a medicine that helps prevent migraines in adults and some older children. It is a shot given under the skin once a month or once every three months. It works by blocking a protein called CGRP that plays a part in causing migraine attacks.
Every report comes from a Lived member, sent anonymously.
Have you tried Ajovy (Fremanezumab) for Migraines?
Fremanezumab, sold as Ajovy, is a prescription injection taken regularly to prevent migraine attacks. It is meant to make attacks less frequent, not to stop a migraine that has already started, so people keep a separate medicine for attacks that still happen. In adults it is approved for both episodic migraine and chronic migraine, which means headaches on 15 or more days a month. Children and teens aged 6 to 17 can use it for episodic migraine (fewer than 15 headache days a month) if they weigh at least 45 kg (about 99 pounds). It is not approved for younger children or for children who weigh less than that. Fremanezumab belongs to a group of migraine-specific preventives that target CGRP (calcitonin gene-related peptide), a protein involved in migraine attacks. Others include the antibodies erenumab (Aimovig) and galcanezumab (Emgality), which are also self-injected, and eptinezumab (Vyepti), which is given by IV infusion, plus the gepants atogepant (Qulipta) and rimegepant (Nurtec ODT), tablets that block the receptor CGRP acts on. Older migraine preventives were first developed for other conditions and later borrowed for migraine. The American Headache Society now says CGRP-targeting medicines can be a first choice for prevention alongside those older options, without someone first having to try and fail them.
CGRP is a natural signaling protein that plays a key role in how a migraine attack starts and builds. Research into its role is what led to a group of medicines designed specifically to prevent migraine, rather than borrowed from other conditions. Fremanezumab is a monoclonal antibody, a lab-made protein designed to latch onto one specific target. It binds to CGRP itself and stops it from attaching to its receptor, so less of the signal gets through. Because the body clears the antibody slowly (about half is gone after a month), one dose keeps working for weeks, which is why it can be given monthly or every three months rather than daily.
Ajovy is injected under the skin of the belly, thigh or upper arm, using a single-use prefilled autoinjector pen or a prefilled syringe. Each device holds 225 mg. A clinician usually shows the person or a caregiver how to inject it, and people 13 and older can do it themselves. For children aged 6 to 12, an adult caregiver or a clinician gives the injection. Adults use one of two schedules: one injection every month, or three injections given one after another once every three months. On the three-month schedule, the three shots can go in the same area of the body, but not in exactly the same spot. Children and teens use the monthly schedule only. The pens and syringes are kept in the refrigerator. Before injecting, the device is left out for about 30 minutes to reach room temperature, without heating it. If a dose is missed, it is given as soon as possible and the next one is counted from that date.
Most people notice little beyond the injection itself. Pain, redness or a firm lump where the needle went in are the most common side effects, though in the trials these were also common with placebo injections. Allergic reactions such as itching, rash or hives can appear within hours or up to a month after a dose and should be reported to the prescriber. Swelling of the face, lips, tongue or throat, or trouble breathing, is a severe allergic reaction that needs emergency help right away. Severe constipation has been reported with this group of antibodies, sometimes leading to hospital stays or surgery. It most often begins after the first dose but can appear later. Contact the care team promptly about constipation that is severe or comes with strong or constant belly pain, vomiting or a swollen belly. Rarely, these medicines can bring on or worsen Raynaud's phenomenon, in which fingers or toes become numb, cold or painful and turn pale, then blue, then red. If this happens, stop the injections and contact the prescriber. In most reported cases symptoms improved after stopping.
Ajovy should not be used by anyone who has had a serious allergic reaction to fremanezumab or any ingredient in the injection. Blood pressure can rise in people who did not have high blood pressure before, or climb further in people who already do. This was reported most often in the first week of treatment, but it can happen at any point. Anyone with high blood pressure should mention it before starting, and anyone who checks their blood pressure at home should report readings that are higher than usual. The pre-approval trials left out people with significant heart or circulation disease, such as a past stroke, so experience in those groups is more limited. Fremanezumab has few drug interactions. It is not broken down by the liver enzymes that cause many interactions, and triptans, other pain relievers and other migraine preventives did not change its levels in studies. The main thing to mention is any medicine that slows the movement of the bowel, because taking one alongside fremanezumab can raise the risk of severe constipation. Opioid pain medicines are the most familiar example, and anticholinergic drugs such as oxybutynin, used for an overactive bladder, also slow the gut. A pharmacist can say whether any other current medicine does this. There is not enough information to know whether fremanezumab is safe in pregnancy or while breastfeeding. Because it stays in the body for months after the last dose, people who are pregnant or planning a pregnancy should discuss timing with their prescriber. The manufacturer runs a pregnancy registry to collect outcomes.
In the main adult trials, results were measured over three months. People with episodic migraine, who started at about nine migraine days a month, averaged three to four fewer migraine days a month, compared with about two fewer on placebo. Roughly 45 to 48 percent cut their migraine days at least in half, compared with 28 percent on placebo. In chronic migraine, about 38 to 41 percent halved their days of moderate or worse headache, versus 18 percent on placebo. Children and teens saw a similar pattern, with smaller average differences. Many people also needed their attack medicine on fewer days. These are averages. Some people improve a great deal and some very little, and placebo injections helped too. In chronic migraine, the difference from placebo was already visible about four weeks after the first dose, though levels in the body keep building for several months. Keeping a headache diary makes it easier to judge whether the injections are worth continuing, compared with another CGRP medicine or a different kind of preventive. Fremanezumab is generally taken for as long as it helps and is tolerated. Its effect fades gradually after the last dose rather than stopping at once.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Ajovy (Fremanezumab), what you've noticed, or ask the community a question.